A 6-week, Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of ZD4522 (5, 10, 20, 40, and 80 mg) and Atorvastatin (10, 20, 40, and 80 mg)Across Their Respective Dose Ranges in the Treatment of Subjects with Hypercholesterolemia
Study identifier:4522IL/0033
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6-week, Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of ZD4522 (5, 10, 20, 40, and 80 mg) and Atorvastatin (10, 20, 40, and 80 mg)Across Their Respective Dose Ranges in the Treatment of Subjects with Hypercholesterolemia
Medical condition
hypercholesterolaemia
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
